Can MicroPort Master Orthopedics?
Executive Summary
China’s MicroPort Scientific paid $290 million in cash for Wright Medical’s hip and knee business, which has a pipeline of products – including FDA approved implants – ready for sale in China’s growing orthopedics market. The acquisition pits MicroPort against multinationals that previously held an edge selling implants to Chinese patients and doctors who seem to favor devices that carry approval from the US FDA.
You may also be interested in...
The Year In Review: Device Trends To Watch In 2014
To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries, but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.
ArthroCare Bid Signals Ortho Consolidation
If completed, Smith & Nephew’s acquisition of ArthroCare would help it diversify into the ENT market, but the deal may not get done as analysts speculate that competitors Stryker and J&J could step in with counteroffers. The interest surrounding ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.
ArthroCare Bid Signals Ortho Consolidation
If completed, Smith & Nephew’s acquisition of ArthroCare would help it diversify into the ENT market, but the deal may not get done as analysts speculate that competitors Stryker and J&J could step in with counteroffers. But the interest surrounding Austin, TX-based ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.